BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 22439807)

  • 1. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
    Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
    Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
    Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
    Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of immunosuppression-induced hypogonadism on bone metabolism after heart transplantation].
    Stief J; Sohn HY; Alt A; Uberfuhr P; Theisen K; Stempfle HU
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1674-8. PubMed ID: 15273918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
    Fairfield WP; Finkelstein JS; Klibanski A; Grinspoon SK
    J Clin Endocrinol Metab; 2001 May; 86(5):2020-6. PubMed ID: 11344201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
    Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
    J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption.
    Anderson FH; Francis RM; Peaston RT; Wastell HJ
    J Bone Miner Res; 1997 Mar; 12(3):472-8. PubMed ID: 9076591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
    Katznelson L; Finkelstein JS; Schoenfeld DA; Rosenthal DI; Anderson EJ; Klibanski A
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4358-65. PubMed ID: 8954042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
    Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
    Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.
    Guo CY; Jones TH; Eastell R
    J Clin Endocrinol Metab; 1997 Feb; 82(2):658-65. PubMed ID: 9024272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects.
    Antonio L; Caerels S; Jardi F; Delaunay E; Vanderschueren D
    Andrology; 2019 May; 7(3):302-306. PubMed ID: 30851011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility.
    Kacker R; Conners W; Zade J; Morgentaler A
    J Urol; 2014 Apr; 191(4):1072-6. PubMed ID: 24161998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone therapy improves the clinical response to conventional treatment for male patients with metabolic syndrome associated to late onset hypogonadism.
    La Vignera S; Calogero AE; D'Agata R; Di Mauro M; Tumino S; Condorelli R; Lanzafame F; Finocchiaro C; Giammusso B; Vicari E
    Minerva Endocrinol; 2008 Sep; 33(3):159-67. PubMed ID: 18846023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
    Saad F; Gooren LJ; Haider A; Yassin A
    J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study.
    Bouloux PM; Legros JJ; Elbers JM; Geurts TB; Kaspers MJ; Meehan AG; Meuleman EJ;
    Aging Male; 2013 Jun; 16(2):38-47. PubMed ID: 23581697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
    Behre HM; Kliesch S; Leifke E; Link TM; Nieschlag E
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2386-90. PubMed ID: 9253305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of bone mineral density and testosterone levels in Korean men with non-mosaic Klinefelter's syndrome.
    Seo JT; Lee JS; Oh TH; Joo KJ
    BJU Int; 2007 Jan; 99(1):141-6. PubMed ID: 17092285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.